Once-daily glycopyrronium bromide a long-acting muscarinic antagonist for chronic obstructive pulmonary disease: a systematic review of clinical benefit

摘要

Background:Long-acting bronchodilators are central in the pharmacological management of patients with chronic obstructive pulmonary disease (COPD). The aim of this systematic review is to provide an overview of the studies evaluating the safety and clinical efficacy of inhaled glycopyrronium bromide, a novel long-acting muscarinic antagonist, in patients with COPD.